Hence, we suggest that the combination of ALK and AXL or HSP90 inhibition could serve as part of an effective strategy of targeted therapeutics for ALKF1174L-driven NB and other tumors dependent on this aberrant RTK. This evidence concerns the gene AXL and neuroblastoma.